Tabula Rasa HealthCare Inc (NASDAQ:TRHC) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Saturday.

According to Zacks, “Tabula Rasa HealthCare, Inc. is a provider of patient-specific, data-driven technology and solutions which enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. The company’s cloud-based software applications including EireneRx and MedWise Advisor which provide solutions to payers, providers and other healthcare organizations. Tabula Rasa HealthCare, Inc. is based in NJ, United States. “

Several other equities analysts have also recently commented on the stock. Robert W. Baird set a $17.00 target price on shares of Tabula Rasa HealthCare and gave the company a “buy” rating in a research report on Thursday, January 19th. Piper Jaffray Companies upped their price objective on shares of Tabula Rasa HealthCare from $18.00 to $19.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 14th. Finally, Stifel Nicolaus upped their price objective on shares of Tabula Rasa HealthCare from $17.00 to $19.00 and gave the stock a “buy” rating in a research report on Tuesday, March 14th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $17.50.

Shares of Tabula Rasa HealthCare (NASDAQ:TRHC) traded down 2.6679% during mid-day trading on Friday, hitting $13.1301. The stock had a trading volume of 19,484 shares. The company’s market cap is $224.17 million. Tabula Rasa HealthCare has a one year low of $10.39 and a one year high of $16.85. The firm’s 50 day moving average price is $13.38 and its 200-day moving average price is $13.54.

Tabula Rasa HealthCare (NASDAQ:TRHC) last issued its earnings results on Monday, March 13th. The company reported $0.10 EPS for the quarter, missing the consensus estimate of $0.11 by $0.01. The firm had revenue of $27.30 million for the quarter, compared to the consensus estimate of $25.53 million. The firm’s revenue was up 37.9% compared to the same quarter last year. On average, equities research analysts anticipate that Tabula Rasa HealthCare will post $0.41 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was reported by Marea Informative and is the property of of Marea Informative. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at http://www.mareainformativa.com/zacks-investment-research-la-rebaja-de-tabula-rasa-healthcare-inc-trhc-para-vender/108274/.

A number of institutional investors have recently added to or reduced their stakes in the company. Taylor Wealth Management Partners acquired a new stake in Tabula Rasa HealthCare during the third quarter worth $2,458,000. Emerald Advisers Inc. PA acquired a new stake in Tabula Rasa HealthCare during the third quarter worth $3,989,000. Emerald Mutual Fund Advisers Trust acquired a new stake in Tabula Rasa HealthCare during the third quarter worth $3,324,000. Wells Fargo & Company MN acquired a new stake in Tabula Rasa HealthCare during the third quarter worth $3,738,000. Finally, Monashee Investment Management LLC acquired a new stake in Tabula Rasa HealthCare during the third quarter worth $4,296,000. Institutional investors and hedge funds own 23.79% of the company’s stock.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.

5 Day Chart for NASDAQ:TRHC

Get a free copy of the Zacks research report on Tabula Rasa HealthCare (TRHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Tabula Rasa HealthCare Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare Inc and related stocks with our FREE daily email newsletter.